


P163-0892

Cat. No.:	HY-150972
CAS No.:	1574576-45-6
Molecular Formula:	C ₁₉ H ₂₀ N ₂ O ₃ S
Molecular Weight:	356.44
Target:	Fungal
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	P163-0892 is a potent and selective antifungal agent against <i>Cryptococcus</i> species. P163-0892 is predicted to show medium BBB penetration ^[1] .									
In Vitro	<p>P163-0892 (0-32 µg/mL; 48 h) shows antifungal activity with a MIC of 0.25 µg/mL and 0.5 µg/mL against <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i>, respectively^[1].</p> <p>P163-0892 has good aqueous solubility^[1].</p> <p>P163-0892 has no cytotoxicity and no obvious cardiotoxicity^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>P163-0892 (10 mg/kg; 5 days) significantly extends the survival of larvae infected with either <i>C. neoformans</i> or <i>C. gattii</i>^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
	Animal Model:	Wax moth larva infected with <i>C. neoformans</i> H99 or <i>C. gattii</i> WM178 ^[1]								
	Dosage:	10 mg/kg								
	Administration:	5 days								
	Result:	Increased the survival rate of larvae.								
	Animal Model:	Male Sprague-Dawley rats weighing 200-250 g ^[1]								
	Dosage:	2 mg/kg or 5 mg/kg								
	Administration:	Intravenous or oral administration (Pharmacokinetic Analysis)								
	Result:	Pharmacokinetic Parameters of P163-0892 ^{a[1]}								
		route	dose (mg/kg)	T _{1/2} (h)	T _{max} (h)	AUC _{0-inf} (h•ng/mL)	Cl (mL/h/kg)	MRT _{0-t} (h)	V _{dss} (L/kg)	BA (%)

iv	2 mg/kg	7.61		749	172	2.63	7.12	
po	5 mg/kg	15.3	3.17	NR		3.83	NR	0.8

^aAbbreviations: iv, intravenous; po, per os; $T_{1/2}$, half-life elimination in hours; T_{max} , time of maximal concentration in hours; AUC, area under the curve; Cl, clearance; MRT, mean residence time; V_{dss} , volume of distribution at the steady state; BA, bioavailability; NR, not reportable; n = 3.

REFERENCES

[1]. Li L, et al. Discovery of Novel 7-Hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide Derivatives with Potent and Selective Antifungal Activity against *Cryptococcus* Species. *J Med Chem*. 2022 Aug 3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA